Growth Factor:
The key features driving the growth of this market include increasing prevalence of breast cancer, increasing preference for non-invasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.
Market Size:
According to the new market research report Breast Cancer Liquid Biopsy Market is expected to reach USD 411.1 million by 2022, at a CAGR of 23.1%.
Top Segments:
By circulating biomarkers, cell-free DNA (cfDNA) is expected to account for the largest market share in 2017
Based
on circulating biomarkers, the market is categorized into circulating
tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vehicles (EVs),
and other circulating biomarkers. In 2017, the cfDNA segment is
expected to account for the largest share of the breast cancer liquid
biopsy market. The ability of cfDNA for easy and early assessment of
patient prognosis and occurrence in other body fluids along with blood
is driving the growth of the cfDNA segment in the breast cancer liquid
biopsy market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150106081
By end user, the reference laboratories segment accounted for the largest market share in 2017
Based
on end user, the breast cancer liquid biopsy market is segmented into
reference laboratories, hospitals and physician laboratories, and other
end users (research institutes, public health laboratories, pathology
laboratories, and small molecular laboratories). Reference laboratories
form the largest and fastest-growing end-user segment of the liquid
biopsy market. The large share of this segment is attributed to the
increasing volume of liquid biopsy test samples outsourced to reference
laboratories owing to their well-equipped set up for genetic testing.
Key players and growth strategies:
The
key players in the global breast cancer liquid biopsy market are QIAGEN
N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc.
(US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy),
Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina,
Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health,
Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
QIAGEN
was the leading player in the breast cancer liquid biopsy market in
2017. The company is a global provider of sample-to-insight solutions
that aids in the transformation of biological samples into molecular
insights. The company operates through its two business segments,
namely, instruments and consumables & related products.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=150106081
